0001214659-18-001759.txt : 20180302
0001214659-18-001759.hdr.sgml : 20180302
20180302180818
ACCESSION NUMBER: 0001214659-18-001759
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180301
FILED AS OF DATE: 20180302
DATE AS OF CHANGE: 20180302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Donadio Jamie A
CENTRAL INDEX KEY: 0001579771
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35921
FILM NUMBER: 18663781
MAIL ADDRESS:
STREET 1: C/O MIRATI THERAPEUTICS, INC.
STREET 2: 9393 TOWNE CENTRE DRIVE, STE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mirati Therapeutics, Inc.
CENTRAL INDEX KEY: 0001576263
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462693615
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9393 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-332-3410
MAIL ADDRESS:
STREET 1: 9393 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
marketforms-41228.xml
PRIMARY DOCUMENT
X0306
4
2018-03-01
0001576263
Mirati Therapeutics, Inc.
MRTX
0001579771
Donadio Jamie A
C/O MIRATI THERAPEUTICS, INC.
9393 TOWNE CENTRE DRIVE, STE 200
SAN DIEGO
CA
92121
false
true
false
false
Sr. VP, CFO
Common Stock
2018-03-01
4
M
false
9375
5.5
A
9375
D
Common Stock
2018-03-01
4
M
false
12500
5.4
A
21875
D
Common Stock
2018-03-01
4
M
false
30000
7.3
A
51875
D
Common Stock
2018-03-01
4
S
false
25600
26.7779
D
26275
D
Common Stock
2018-03-01
4
S
false
25775
27.4526
D
500
D
Common Stock
2018-03-01
4
S
false
500
28.08
D
0
D
Employee Stock Option (Right to Buy)
5.5
2018-03-01
4
M
false
9375
0
D
2026-10-26
Common Stock
9375
20625
D
Employee Stock Option (Right to Buy)
5.4
2018-03-01
4
M
false
12500
0
D
2027-01-25
Common Stock
12500
37500
D
Employee Stock Option (Right to Buy)
7.30
2018-03-01
4
M
false
30000
0
D
2020-03-19
Common Stock
30000
0
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2017.
1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
Twenty percent (20%) of the shares subject to the stock option vested and became exercisable on the grant date of the option (March 20, 2013), and an additional 20% shall vest and become exercisable each year on the anniversary of the grant date.
This transaction was executed in multiple trades at prices ranging from $26.05 to $27.025. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $27.05 to $28.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $28.05 to $28.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
/s/ Jamie Donadio
2018-03-02